AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26997243 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 153
Study 26997243 — intervention group
Group type: COMPARATOR
Intervention: Sham-CPAP
Number of subjects: 153
Study 24702550 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time (FT) faculty
Number of subjects: 881
Study 24702550 — intervention group
Group type: COMPARATOR
Intervention: Part-time (PT) faculty
Number of subjects: 881
Study 22521274 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 942
Study 22521274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 942
Study 20299191 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 0
Study 20299191 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 0
Study 18033754 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib (4 weeks)
Number of subjects: 19
Study 18033754 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib added to atorvastatin (4 weeks)
Number of subjects: 19
Study 18033754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 weeks)
Number of subjects: 19
Study 15830247 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous abscess incision and tooth extraction
Number of subjects: 177
Study 15830247 — intervention group
Group type: COMPARATOR
Intervention: Separate abscess incision and tooth extraction
Number of subjects: 177
Study 15830247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 177
Study 12867898 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 67
Study 12867898 — intervention group
Group type: COMPARATOR
Intervention: Uvulopalatopharyngoplasty (UPPP)
Number of subjects: 67
Study 10577754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine
Number of subjects: 21
Study 10577754 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 21
Study 10577754 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine and naloxone
Number of subjects: 21
Study 8831087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized tobramycin
Number of subjects: 12
Study 8831087 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 12
Study 8831087 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline oxygen saturation
Number of subjects: 12
Study 8831087 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 12
Study 1914458 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-IUD
Number of subjects: 8
Study 1914458 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-IUD
Number of subjects: 8
Study 1914458 — intervention group
Group type: EXPERIMENTAL
Intervention: Inert IUD
Number of subjects: 8
Study 1914458 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro experiment with copper-IUD
Number of subjects: 8
Study 6870623 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid (100 mg/kg every four hours for five days, max 30 g daily)
Number of subjects: 48
Study 6870623 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical regimen to aminocaproic acid)
Number of subjects: 48
Study 6870623 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid
Number of subjects: 48
Study 6870623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30835505 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-scaled SCUs caring for up to 8 residents, duration 6 months
Number of subjects: 145
Study 30835505 — intervention group
Group type: COMPARATOR
Intervention: Large-scaled SCUs caring for 20-30 residents, duration 6 months
Number of subjects: 145
Study 30928395 — intervention group
Group type: EXPERIMENTAL
Intervention: Total shoulder arthroplasty (TSA)
Number of subjects: 37
Study 27825616 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg orally daily
Number of subjects: 19
Study 26397228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib treatment with low LDH serum levels
Number of subjects: 71
Study 26397228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib treatment with high LDH serum levels
Number of subjects: 71
Study 26397228 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without sorafenib
Number of subjects: 71
Study 23314221 — intervention group
Group type: EXPERIMENTAL
Intervention: Real left DLPFC rTMS
Number of subjects: 14
Study 23314221 — intervention group
Group type: COMPARATOR
Intervention: Sham left DLPFC rTMS
Number of subjects: 14
Study 23314221 — intervention group
Group type: COMPARATOR
Intervention: Naloxone pretreatment
Number of subjects: 14
Study 23314221 — intervention group
Group type: COMPARATOR
Intervention: Saline pretreatment
Number of subjects: 14
Study 20960320 — intervention group
Group type: EXPERIMENTAL
Intervention: ioMRI-guided tumor resection
Number of subjects: 29
Study 20960320 — intervention group
Group type: COMPARATOR
Intervention: Conventional microneurosurgical tumor resection
Number of subjects: 29
Study 19524577 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion for 72 hours
Number of subjects: 173
Study 19524577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose) infusion for 72 hours
Number of subjects: 173
Study 17514187 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam-XR
Number of subjects: 30
Study 17514187 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam-CT
Number of subjects: 30
Study 15213040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary inorganic sulfur intake (0.17-0.27 g S/d)
Number of subjects: 47
Study 15213040 — intervention group
Group type: EXPERIMENTAL
Intervention: Average protein intake (72 g/d)
Number of subjects: 47
Study 15213040 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical UK intakes of inorganic sulfur (0.25 g/d)
Number of subjects: 47
Study 15213040 — intervention group
Group type: EXPERIMENTAL
Intervention: Twenty-four-hour urinary nitrogen and sulfate values
Number of subjects: 47
Study 10971248 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated group (n = 15; Quadrox Bioline oxygenator/reservoir and Carmeda BioMedicus BP-80 centrifugal pump)
Number of subjects: 27
Study 10971248 — intervention group
Group type: COMPARATOR
Intervention: Non-heparin-coated group (n = 12; uncoated oxygenator, centrifugal pump, tubing, and filter set)
Number of subjects: 27
Study 10971248 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated group (n = 15)
Number of subjects: 27
Study 10971248 — intervention group
Group type: COMPARATOR
Intervention: Non-heparin-coated group (n = 12)
Number of subjects: 27
Study 8780205 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal
Number of subjects: 7
Study 8780205 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic clamping
Number of subjects: 7
Study 1520018 — intervention group
Group type: EXPERIMENTAL
Intervention: KabiVial 16 IU/ml combined with an Auto Injector
Number of subjects: 30
Study 1520018 — intervention group
Group type: COMPARATOR
Intervention: KabiPen 16 IU/ml
Number of subjects: 30
Study 6386819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 284
Study 6386819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 31522106 — intervention group
Group type: COMPARATOR
Intervention: control with visual feedback
Number of subjects: 60
Study 31522106 — intervention group
Group type: COMPARATOR
Intervention: control without visual feedback
Number of subjects: 60
Study 31522106 — intervention group
Group type: EXPERIMENTAL
Intervention: fatigue with visual feedback
Number of subjects: 60
Study 31522106 — intervention group
Group type: EXPERIMENTAL
Intervention: fatigue without visual feedback
Number of subjects: 60
Study 29768524 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 layers of PRF membranes + CAF (test group-1)
Number of subjects: 63
Study 29768524 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 layers of PRF membranes + CAF (test group-2)
Number of subjects: 63
Study 29768524 — intervention group
Group type: COMPARATOR
Intervention: CTG + CAF (control group)
Number of subjects: 63
Study 29768524 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF membrane + CAF technique
Number of subjects: 63
Study 1481500 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvesorb
Number of subjects: 96
Study 22040840 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 41
Study 22040840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 20422436 — intervention group
Group type: EXPERIMENTAL
Intervention: J-pouch
Number of subjects: 273
Study 20422436 — intervention group
Group type: COMPARATOR
Intervention: Side to end anastomosis (STEA)
Number of subjects: 273
Study 18760135 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Overdrive Pacing ON (AOP ON)
Number of subjects: 409
Study 18760135 — intervention group
Group type: COMPARATOR
Intervention: Atrial Overdrive Pacing OFF (AOP OFF)
Number of subjects: 409
Study 18760135 — intervention group
Group type: EXPERIMENTAL
Intervention: AOP ON
Number of subjects: 409
Study 18760135 — intervention group
Group type: COMPARATOR
Intervention: AOP OFF
Number of subjects: 409
Study 15870187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocinaplon (total daily dose of 180-240 mg)
Number of subjects: 0
Study 15870187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12676074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ben 10 mg/d, po
Number of subjects: 90
Study 12676074 — intervention group
Group type: EXPERIMENTAL
Intervention: Val 80 mg/d, po
Number of subjects: 90
Study 12676074 — intervention group
Group type: EXPERIMENTAL
Intervention: Val 80 mg/d + Ben 10 mg/d, po
Number of subjects: 90
Study 12676074 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 normal subjects)
Number of subjects: 90
Study 10655910 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic monitoring (MIC)
Number of subjects: 25
Study 9125796 — intervention group
Group type: EXPERIMENTAL
Intervention: Current therapeutic modalities for RPGN
Number of subjects: 0
Study 9125796 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging therapeutic options for RPGN
Number of subjects: 0
Study 1829372 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms h‐ANP 99‐126 intravenously for 30 min during placebo
Number of subjects: 10
Study 1829372 — intervention group
Group type: COMPARATOR
Intervention: 50 mg carbidopa every 8 h during ANP infusion
Number of subjects: 10
Study 6421344 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU, cyclophosphamide, and prednisone
Number of subjects: 0
Study 6421344 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug regimen (sodium fluoride, vitamin D, calcium gluconate, fluoxymesterone)
Number of subjects: 0
Study 6421344 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study 6421344 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone
Number of subjects: 0
Study 30788777 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct pulp capping (DPC)
Number of subjects: 74
Study 30788777 — intervention group
Group type: COMPARATOR
Intervention: Pulpotomy
Number of subjects: 74
Study 29880047 — intervention group
Group type: EXPERIMENTAL
Intervention: SMI Patient‐Aligned Care Team (SMI PACT)
Number of subjects: 0
Study 29880047 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27253829 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA administration in CYP2D6 poor metabolizers
Number of subjects: 139
Study 24184589 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming warm-up plus IME warm-up (2 sets of 30 breaths with a 40% maximum inspiratory mouth pressure load)
Number of subjects: 15
Study 24184589 — intervention group
Group type: COMPARATOR
Intervention: IME-only warm-up (2 sets of 30 breaths with a 40% maximum inspiratory mouth pressure load)
Number of subjects: 15
Study 24184589 — intervention group
Group type: COMPARATOR
Intervention: Swimming warm-up only
Number of subjects: 15
Study 22072272 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment 3×/wk during radiotherapy
Number of subjects: 86
Study 22072272 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 86
Study 20466163 — intervention group
Group type: EXPERIMENTAL
Intervention: Premix insulin (biphasic insulin aspart 30 [NovoMix 30])
Number of subjects: 60000
Study 20466163 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin (insulin detemir [Levemir])
Number of subjects: 60000
Study 20466163 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-time insulin (insulin aspart [NovoRapid])
Number of subjects: 60000
Study 20466163 — intervention group
Group type: EXPERIMENTAL
Intervention: All insulin analogs
Number of subjects: 60000
Study 17676985 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis with Deltaprim (3.125 mg of pyrimethamine plus 25 mg of dapsone)
Number of subjects: 415
Study 17676985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 18830034 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-bisphosphonates
Number of subjects: 0
Study 15182119 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) for three continuous hours
Number of subjects: 24
Study 15182119 — intervention group
Group type: COMPARATOR
Intervention: Standard NICU care
Number of subjects: 24
Study 11329231 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone, 400 mg/d
Number of subjects: 200
Study 11329231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9291302 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated varicella vaccine (single dose at 1 month after transplantation)
Number of subjects: 75
Study 9291302 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated varicella vaccine (three doses at 1, 2, and 3 months after transplantation)
Number of subjects: 75
Study 9291302 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated varicella vaccine (three doses)
Number of subjects: 75
Study 8409112 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-1078, 150 mg capsule, administered every 12 hours for 1 week
Number of subjects: 0
Study 8409112 — intervention group
Group type: COMPARATOR
Intervention: Placebo, inactive, administered every 12 hours for 1 week
Number of subjects: 0
Study 3516203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200 mg daily)
Number of subjects: 28
Study 3516203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11555165 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐Hz magnetic fields at an intensity of 28.3 microTesla (microT)
Number of subjects: 46
Study 11555165 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure under equivalent, counter‐balanced, no‐exposure (<= 0.2 microT)
Number of subjects: 46
Study 11555165 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐Hz magnetic fields
Number of subjects: 46
Study 11555165 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 46
Study 30142300 — intervention group
Group type: EXPERIMENTAL
Intervention: MI‐SafeCope
Number of subjects: 36
Study 30142300 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 36
Study 29444611 — intervention group
Group type: EXPERIMENTAL
Intervention: Goreisan (7.5 g daily for 12 weeks)
Number of subjects: 180
Study 29444611 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 180
Study 27554053 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli LPS (2 ng/kg)
Number of subjects: 17
Study 27554053 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nicotine patch (applied 10 hours previously)
Number of subjects: 17
Study 24617755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led case management programme
Number of subjects: 281
Study 24617755 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 281
Study 22549090 — intervention group
Group type: EXPERIMENTAL
Intervention: GTU(®)-Multi-HIVB vaccine (1mg/dose IM at 0, 4, 12 weeks, boosted at 76 and 80 weeks with 2mg/dose)
Number of subjects: 63
Study 22549090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 19733353 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 19733353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17276548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin/acetaminophen combination therapy
Number of subjects: 90
Study 17276548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone/acetaminophen combination therapy
Number of subjects: 90
Study 17276548 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 90
Study 16198660 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59‐‐7939 (1.25‐‐80 mg)
Number of subjects: 108
Study 16198660 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59‐‐7939 (5‐mg tablet and oral solution)
Number of subjects: 108
Study 16198660 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 59‐‐7939
Number of subjects: 108
Study 16198660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 12189361 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (900 mg oral administration)
Number of subjects: 44
Study 12189361 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 44
Study 12189361 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/CMV-positive patients
Number of subjects: 44
Study 10321486 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-to-whole face processing
Number of subjects: 0
Study 10321486 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-to-part face processing
Number of subjects: 0
Study 10321486 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole faces and isolated eyes
Number of subjects: 0
Study 8849180 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline plus ketoprofen (doxycycline 100 mg twice daily for 10 days plus ketoprofen 200 mg daily for 10 days)
Number of subjects: 65
Study 8849180 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 10 days)
Number of subjects: 65
Study 2216372 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 40
Study 2216372 — intervention group
Group type: COMPARATOR
Intervention: Nonrigid fixation
Number of subjects: 40
Study 100202 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (4500 rad over five weeks)
Number of subjects: 0
Study 100202 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 0
Study 31561728 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training Group (TG)
Number of subjects: 25
Study 31561728 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 25
Study 30043183 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression socks (SOCK, n=34)
Number of subjects: 67
Study 30043183 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONTROL, n=33)
Number of subjects: 67
Study 26991494 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A
Number of subjects: 12
Study 26991494 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A-B
Number of subjects: 12
Study 26991494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 12
Study 25198268 — intervention group
Group type: EXPERIMENTAL
Intervention: Random biopsy
Number of subjects: 388
Study 21733319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio nuts (0, 42, and 84 g/d)
Number of subjects: 16
Study 21148614 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg) once daily
Number of subjects: 889
Study 21148614 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 889
Study 17320313 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking the first cigarette of the day
Number of subjects: 207
Study 17320313 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater decreases in craving as measured by the QSU‐Brief
Number of subjects: 207
Study 15780846 — intervention group
Group type: COMPARATOR
Intervention: 0 mg Delta‐9‐THC
Number of subjects: 13
Study 15780846 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg Delta‐9‐THC
Number of subjects: 13
Study 15780846 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Delta‐9‐THC
Number of subjects: 13
Study 12860330 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers at conception
Number of subjects: 1437
Study 12860330 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers reporting <15 cigarettes per day
Number of subjects: 1437
Study 12860330 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers reporting >=15 cigarettes per day
Number of subjects: 1437
Study 12860330 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who quit smoking 1 year or more before conception
Number of subjects: 1437
Study 12860330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes smoked during the first trimester of pregnancy
Number of subjects: 1437
Study 12860330 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner's smoking
Number of subjects: 1437
Study 10832257 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent articaine with epinephrine 1:100,000
Number of subjects: 1325
Study 10832257 — intervention group
Group type: COMPARATOR
Intervention: 2 percent lidocaine with epinephrine 1:100,000
Number of subjects: 1325
Study 8857500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol at 0.025%
Number of subjects: 0
Study 8857500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol at 0.05%
Number of subjects: 0
Study 8857500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol at 0.75%
Number of subjects: 0
Study 1996738 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 6mg/kg per day for 12 days
Number of subjects: 30
Study 1996738 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin 200 mcg/kg
Number of subjects: 30
Study 1996738 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin 400 mcg/kg (200 mcg/kg per day for 2 days)
Number of subjects: 30